MKI67 and neoplasm: There was also a similar reduction in tumor weight (vehicle 0.39 ± 0.04 g, trametinib 0.21 ± 0.05 g, cediranib 0.30 ± 0.12 g, and trametinib + cediranib 0.03 ± 0.01 g; p < 0.01) (Fig. 3A,B), and a significant decrease in proliferation in the combination group compared with either treatment alone as assessed by Ki67 immunohistochemistry (Supp Fig. S1A,B).